



Year: 2019

Long-term prognostic value of coronary flow reserve in psoriasis patients

Piaserico, Stefano ; Osto, Elena ; Famoso, Giulia ; Montisci, Roberta ; De Michieli, Laura ; Zanetti, Irene ; Iliceto, Sabino ; Tona, Francesco

Abstract: BACKGROUND AND AIMS Psoriasis affects more than 3% of the general population and is associated with an increased risk of premature cardiovascular events and death. We assessed the prognostic role of coronary flow reserve (CFR) as a marker of coronary microvascular function in psoriasis patients asymptomatic for cardiovascular disease. METHODS We retrospectively analyzed 153 prospectively collected patients affected by psoriasis (123 male; age 36 ± 8 years) without cardiovascular disease. CFR in the left anterior descending coronary artery was detected by transthoracic Doppler echocardiography, at rest, and during adenosine infusion. CFR was the ratio of hyperemic to resting diastolic flow velocity. CFR ≥ 2.5 was the cut off to define the presence of coronary microvascular dysfunction (CMD). RESULTS CMD was present in 23 patients (15%). Multivariable logistic regression analysis showed that CMD was associated with severe psoriasis (OR 3.1, $p = 0.03$), psoriatic arthritis (OR 2.9, $p = 0.03$), hypertension (OR 4.1, $p = 0.009$), and time elapsing since psoriasis diagnosis >6 years (OR 1.9, $p = 0.03$). Patients with CFR ≥ 2.5 had a lower survival free from events ($p < 0.0001$). CONCLUSIONS In psoriasis patients, CFR may be a reliable prognostic marker for cardiovascular event-free survival and may help identify patients at higher risk of developing cardiovascular complications. Whether novel biologic therapies able to reduce skin disease will improve CMD and prognosis in these patients needs to be further studied, prospectively.

DOI: <https://doi.org/10.1016/j.atherosclerosis.2019.08.009>

Posted at the Zurich Open Repository and Archive, University of Zurich

ZORA URL: <https://doi.org/10.5167/uzh-184904>

Journal Article

Accepted Version



The following work is licensed under a Creative Commons: Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.

Originally published at:

Piaserico, Stefano; Osto, Elena; Famoso, Giulia; Montisci, Roberta; De Michieli, Laura; Zanetti, Irene; Iliceto, Sabino; Tona, Francesco (2019). Long-term prognostic value of coronary flow reserve in psoriasis patients. *Atherosclerosis*, 289:57-63.

DOI: <https://doi.org/10.1016/j.atherosclerosis.2019.08.009>

Manuscript Number: ATH-D-19-00309R2

Title: Long-term prognostic value of coronary flow reserve in psoriasis patients

Article Type: Research paper

Section/Category: Clinical & Population Research

Keywords: psoriasis; coronary microcirculation; prognosis; coronary flow reserve; cardiovascular risk

Corresponding Author: Professor Francesco Tona,

Corresponding Author's Institution:

First Author: Stefano Piaserico

Order of Authors: Stefano Piaserico; Elena Osto; Giulia Famoso; Roberta Montisci; Laura De Michieli; Irene Zanetti; Sabino Iliceto; Francesco Tona

Abstract: Background and Aims: Psoriasis affects more than 3% of the general population and is associated with an increased risk of premature cardiovascular events and death. We assessed the prognostic role of coronary flow reserve (CFR) as a marker of coronary microvascular function in psoriasis patients asymptomatic for cardiovascular disease. **Methods:** We retrospectively analyzed 153 prospectively collected patients affected by psoriasis (123 male; age, 36±8 years) without cardiovascular disease. CFR in the left anterior descending coronary artery was detected by transthoracic Doppler echocardiography, at rest, and during adenosine infusion. CFR was the ratio of hyperemic to resting diastolic flow velocity. CFR ≤2.5 was the cut off to define the presence of coronary microvascular dysfunction (CMD).


Results: CMD was present in 23 patients (15%). Multivariable logistic regression analysis showed that CMD was associated with severe psoriasis (OR 3.1, p=0.03), psoriatic arthritis (OR 2.9, p=0.03), hypertension (OR 4.1, p=0.009), and time elapsing since psoriasis diagnosis >6 years (OR 1.9, p=0.03). Patients with CFR ≤2.5 had a lower survival free from events (p<0.0001).

Conclusions: In psoriasis patients, CFR may be a reliable prognostic marker for cardiovascular event-free survival and may help to identify patients at higher risk of developing cardiovascular complications. Whether novel biologic therapies able to reduce skin disease will improve CMD and prognosis in these patients needs to be further studied, prospectively.

Highlights

- This study analyzed the prognostic role of coronary flow reserve in psoriasis.
- 153 psoriatic patients without cardiovascular disease were included.
- Coronary microvascular dysfunction was present in 15% of patients.
- Coronary flow reserve may be a prognostic marker for events-free survival.

In psoriasis patients, the assessment of coronary microvascular dysfunction (CMD) may identify patients with worse cardiovascular outcome. These results provide a rationale for assessing CMD and to identify psoriasis patients at higher risk for developing cardiovascular complications.



1
2
3 **Long-term prognostic value of coronary flow reserve in psoriasis patients**
4
5
6
7
8

9
10 Stefano Piaserico, MD, PhD^{a1}; Elena Osto, MD, PhD^{b,c1}; Giulia Famoso, MD, PhD^d; Roberta
11 Montisci, MD^e; Laura De Michieli, MD^d; Irene Zanetti, MD^d; Sabino Iliceto, MD^d; Francesco Tona,
12
13 MD, PhD^{d*}
14
15
16
17
18

19 ^aDermatology Unit, Department of Medicine, ^b University Heart Center and ^cInstitute of Clinical
20 Chemistry, University Hospital Zurich, Zurich, Switzerland, Department of Cardiac, Thoracic,
21 Vascular Sciences and Public Health, University of Padova, Padova, Italy, ^eClinical Cardiology,
22 Department of Medical Science and Public Health , University of Cagliari, Cagliari, Italy
23
24
25
26
27
28
29
30

31 *Corresponding author and person to whom reprint requests should be addressed:*

32 ¹ these authors contributed equally.
33
34

35 *Francesco Tona, MD, PhD
36 Department of Cardiac, Thoracic, Vascular Sciences and Public Health
37 University of Padova, Padova, Italy
38 Phone: +390498211844
39 Fax: +390498211802
40 Email: francesco.tona@unipd.it
41
42
43
44

45
46 **Running title:** Coronary microcirculation in psoriasis
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Abstract

Background and Aims: Psoriasis affects more than 3% of the general population and is associated with an increased risk of premature cardiovascular events and death. We assessed the prognostic role of coronary flow reserve (CFR) as a marker of coronary microvascular function in psoriasis patients asymptomatic for cardiovascular disease.

Methods: We retrospectively analyzed 153 prospectively collected patients affected by psoriasis (123 male; age, 36 ± 8 years) without cardiovascular disease. CFR in the left anterior descending coronary artery was detected by transthoracic Doppler echocardiography, at rest, and during adenosine infusion. CFR was the ratio of hyperemic to resting diastolic flow velocity. $\text{CFR} \leq 2.5$ was the cut off to define the presence of coronary microvascular dysfunction (CMD).

Results: CMD was present in 23 patients (15%). Multivariable logistic regression analysis showed that CMD was associated with severe psoriasis (OR 3.1, $p=0.03$), psoriatic arthritis (OR 2.9, $p=0.03$), hypertension (OR 4.1, $p=0.009$), and time elapsing since psoriasis diagnosis >6 years (OR 1.9, $p=0.03$). Patients with $\text{CFR} \leq 2.5$ had a lower survival free from events ($p<0.0001$).

Conclusions: In psoriasis patients, CFR may be a reliable prognostic marker for cardiovascular event-free survival and may help to identify patients at higher risk of developing cardiovascular complications. Whether novel biologic therapies able to reduce skin disease will improve CMD and prognosis in these patients needs to be further studied, prospectively.

Key words: psoriasis, coronary microcirculation, prognosis, coronary flow reserve, cardiovascular risk

Introduction

Patients affected by psoriasis, similarly to other chronic inflammatory systemic immune-mediated diseases, such as rheumatoid arthritis (RA), systemic lupus erythematosus (SLE) and systemic sclerosis (SSc), suffer from increased cardiovascular morbidity and mortality due to premature and accelerated atherosclerosis (1).

Systemic chronic inflammation is regarded as a major causal mechanism leading to atherosclerosis-driven clinical and subclinical coronary artery disease in patients with psoriasis and other immune-mediated diseases. (2,3).

Recent positive results obtained by monoclonal antibodies against interleukin (IL)-1b in secondary prevention of cardiovascular events in patients with coronary artery disease and residual inflammatory risk, further support inflammation as a therapeutic target in atherosclerosis (4).

Indeed, in patients with severe psoriasis, biologic therapies (i.e. anti TNF α , anti-IL-12/23 and anti-IL-17) were associated with favorable modulation of coronary plaque characteristics on the short term and anti TNF α decreased risk for myocardial infarction over a longer period of treatment (5,6).

Coronary microvascular dysfunction (CMD) describes a disease entity common to various clinical situations in which a reduced coronary flow reserve (CFR) (i.e. the ratio between blood flow during maximal coronary vasodilation and resting flow) along with evidence of myocardial ischaemia are not secondary to epicardial coronary artery stenosis (7). We previously reported in young patients with psoriasis, without traditional cardiovascular risk factors or angiographic evidence for coronary artery disease, higher prevalence of CMD detected by CFR measured by transthoracic Doppler echocardiography (TDE). In these patients, the degree of CMD was directly correlated to the disease severity evaluated by the Psoriasis Area Severity Index (PASI) (8) and CFR was

improved by anti-TNF α therapy, which is commonly considered as the first line biologic agent for the treatment of psoriasis (9).

Emerging data documents that CMD, despite the absence of obstructive CAD, is not a benign condition. Indeed, in patients with systemic immune-mediated diseases like SSc, CMD is associated to higher risk of adverse cardiovascular outcomes (10).

The starting hypothesis of our work is that even in patients with psoriasis the CMD may play a prognostic role. Consequently, the aim and the novelty of the present study was to characterize in patients with moderate-to-severe psoriasis the cardiovascular long-term prognostic value of impaired CFR detected by TDE, as a cost-effective tool to risk-stratify young patients with CMD without hemodynamically significant stenosis as detected by coronary multi-slice computed tomography [MSCT].

Material and Methods

This study is a retrospective analysis of prospectively collected data at a single center. We enrolled 153 consecutive patients affected by moderate-to-severe psoriasis (123 male; mean age, 36 \pm 8 years, range 18-50), recruited between January 2009 and December 2015. All patients had a diagnosis of moderate to severe psoriasis since at least 12 months, stable plaque psoriasis since at least 2 months before screening. Patients were included if they met the following inclusion criteria: available CFR and MSCT evaluation, age <50 years, no symptoms or history of cardiovascular disease. The following risk factors for coronary artery disease were assessed at the time of CFR evaluation: hypertension, diabetes mellitus, hypercholesterolemia, smoking, high-sensitive C-reactive protein (hsCRP), family history of heart disease, body mass index (BMI). For risk factors definition see Supplementary Material online. Exclusion criteria were high blood pressure at CFR evaluation, history or clinical evidence of renal (serum creatinine >133 μ mol/L in

men and $>120 \mu\text{mol/L}$ in women), or hepatic disease and malignant or infectious disease. The activity of psoriasis was determined using the validated disease-specific activity index PASI.

Psoriasis Area Severity Index (PASI) evaluation

The body is divided into four regions comprising the head, upper extremities, trunk, and lower extremities. In each of these areas, the fraction of total surface area affected is graded on a 0–6 scale (0 for no involvement up to 6 for greater than 90% involvement). The various body regions are weighted to reflect their respective proportion of body surface area. The composite PASI score is then calculated by multiplying the sum of the individual-severity scores for each region by the weighted area-of-involvement score for that respective region, and then summing the four resulting quantities. The highest potential PASI score is 72; the lowest is 0. PASI scores are nearly continuous, with 0.1 increments within these values. PASI 5–10 defined moderate psoriasis, PASI >10 defined a severe psoriasis.

Echocardiography methods and coronary flow velocity reserve assessment

Transthoracic Doppler echocardiography was performed with a commercially available ultrasound system (Vivid 7, GE Medical System, Inc., Hortem, Norway). Doppler echocardiography and CFR assessment has been previously detailed (11–14). A $\text{CFR} \leq 2.5$ was considered abnormal (15), and the population was dichotomized according to this cutoff.

MSCT coronary angiography protocol and interpretation

Patients with abnormal CFR underwent to MSCT coronary angiography to exclude epicardial significant CAD and to measure calcium score. Coronary MSCT was performed using a 64-slice dual-source scanner (Definition, Siemens Medical System, Forchheim, Germany). MSCT protocol and interpretation has been previously detailed (16).

Adverse outcomes during follow-up

Subjects were followed prospectively to a combined endpoint of major adverse cardiovascular

events (MACE). During a follow up performed every 3 months, records of patients reporting an event were reviewed by an events committee blinded to CFR evaluation and tabulated as death, nonfatal myocardial infarction (MI), nonfatal stroke; and hospital stay for congestive heart failure (CHF), angina, and other vascular events. Those with death, nonfatal MI, nonfatal stroke, or CHF hospital stay were categorized as having MACE. Angina and myocardial infarctions were defined by ESC guidelines (17,18).

Statistical analysis

Continuous variables with no/mild skew were presented as mean \pm SD; skewed measures were represented as median with first and third quartiles (Q1-Q3). Discrete variables were summarized as frequencies and percentages. The distribution of the data was analysed with a 1-sample Kolmogorov-Smirnov test. Categorical variables were compared by the χ^2 test or the Fisher exact test as appropriate. Continuous data were compared by use of the 2-tailed paired or unpaired t test (for normally distributed data sets) or the Mann-Whitney U or Wilcoxon signed-rank test (for skewed variables). Stepwise logistic regression analysis was used to model normal versus abnormal CFR (≤ 2.5) and risk factors. Baseline characteristics were chosen for entry into multivariable models on the basis of their discrimination between normal and abnormal CFR and on unadjusted association with CFR ≤ 2.5 of $p \leq 0.1$. In order to account for possible modulator effects, we then forced all other variables from Table 1 into the model, one at a time. A combination of forward and backward selection procedures was used to aid in determining the best model of factors independently associated with CFR ≤ 2.5 . Median values for age, severity of psoriasis and duration of psoriasis were selected as a cut point for simplicity in the multivariable analysis. Summary statistics for the regression models included the c -statistic (a measure of association of predicted probabilities and observed prevalence of a binary outcome) and R^2 (rescaled for use in logistic regression). As for the retrospective follow-up, stepwise logistic

1 regression analysis was also used to model event versus non event (as dependent variable) and
2
3 CMD. Event-free survival curves were traced by use of the Kaplan-Meier method and compared by
4
5 log-rank test. All tests were two-sided and statistical significance was accepted if the null
6
7 hypothesis could be rejected at $p < 0.05$. Data were analyzed with SPSS software version 24.0
8
9 (Chicago, SPSS, Inc., Chicago, Illinois). The authors had full access to the data and take full
10
11 responsibility for its integrity. All authors have read and agree to the manuscript as written. The
12
13 study protocol was reviewed and approved by the institutional ethical committee. All participants
14
15 gave their written informed consent to participate in the study.
16
17
18
19
20

21 **Sample size determination**

22 Although the study sample size was limited, a priori power calculations based on a one tailed t-test
23
24 to obtain a power of 0.80, a significance level of 0.05 and an effect size based on published values
25
26 of standard deviations and MACE incidence in moderate-to-severe psoriasis, would estimate that
27
28 with 1:1 matching of patients without CMD and patients with CMD and an assumed relative
29
30 survival free from MACE of 0.8 in the group with CMD, we would need approximately 34 patients
31
32 in each group to show a difference.
33
34
35
36
37

38 A post-hoc power analysis (assuming $\alpha = 0.05$) estimated that with 130 patients without CMD and
39
40 23 patients with CMD, with an event incidence of 0% in patients without CMD and 21% in patients
41
42 with CMD, we reject the null hypothesis of equal survival with 94.1% power.
43
44
45
46
47

48 **Results**

49 **Baseline characteristics**

50
51 There were no adverse reactions to adenosine. The baseline characteristics of the 153 patients are
52
53 summarized in Table 1. The mean duration of follow-up was 5.53 ± 2.42 years (range, 0.6 to 9.4
54
55 years). The study population included 24 (15.7%) subjects with hypertension, 57 (37.2%) with
56
57
58
59
60
61
62
63
64
65

hypercholesterolemia, 52 (33.9%) current cigarette smokers and 36 (23.5%) with a family history of heart disease. No patient was diabetic. Mean BMI was 26.3 ± 4 . Total cholesterol was 194 ± 43 mg/dL, and triglycerides were 110 ± 61 mg/dL. In the whole study group CFR was 3.16 ± 0.79 . On individual patient analysis, CFR was >2.5 in 130 patients (84.9%), and ≤ 2.5 in 23 patients (15.1%). The presence of epicardial artery stenosis was excluded by MSCT in all of 23 patients with $CFR \leq 2.5$ and Calcium Score was <10 in all patients with $CFR \leq 2.5$. For hemodynamic parameters during CFR evaluation see the Supplementary results online.

Characteristics of patients with CMD ($CFR \leq 2.5$)

Patients with CMD were older (40 ± 9 vs 37 ± 7 years, $p=0.03$), had a greater severity of psoriasis (PASI 18 [11-20] vs 13 [11-15], $p=0.02$), a longer time elapsing since psoriasis diagnosis (17 [10-26] vs 14 [9-21] years, $p=0.03$), and more frequently had psoriatic arthritis (52.4% vs 29.3%, $p=0.03$), hypertension (38.1% vs 12.0%, $p=0.003$) and family history of heart disease (42.9% vs 20.3%, $p=0.024$) (Table 1).

Factors associated with CMD ($CFR \leq 2.5$)

In unadjusted logistic regression analysis, the significant or marginally significant ($p \leq 0.1$) risk factors were age ($p=0.03$), time elapsing since psoriasis diagnosis >6 years ($p=0.03$), hypertension ($p=0.002$), PASI >10 ($p=0.09$), and PsA ($p=0.1$). Factors independently associated with CMD are summarized in Table 2. When modelled using a stepwise regression and adjusting for baseline differences and predictors at unadjusted logistic regression analysis, the factors independently associated with CMD were time elapsing since psoriasis diagnosis >6 years and hypertension ($p=0.03$ and $p=0.007$, respectively) (Table 2). The inclusion of heart rate-pressure product did not greatly affect the model and no other clinical characteristic entered as a significant covariate. To exclude the modulating effect of other variables, we also added variables marginally significant in unadjusted analysis (model 2). In this model, PASI >10 and PsA were also independently associated

with CMD, but their addition to the model did not significantly affect the relationship between CMD and hypertension or time elapsing since psoriasis diagnosis >6 years (Table 2). When other conditions (current smoking, BMI, and total cholesterol) were forced into the model (potentially overfitting it), time elapsing since psoriasis diagnosis >6 years and hypertension remained significantly associated with CMD ($p=0.03$ and $p=0.02$, respectively) (model 3).

Major adverse cardiac events

A total of 5 patients experienced a MACE. All of them had a $CFR \leq 2.5$ at the beginning of the study.

Three patients experienced a type 1 myocardial infarction. One vessel critical epicardial stenosis was diagnosed in 2 patients, which were treated with percutaneous revascularization. Three vessels critical epicardial stenosis was diagnosed in only one patient treated with surgical revascularization. Epicardial coronary arteries were normal in the other 2 patients with MINOCA (myocardial infarction with non-obstructive coronary arteries) (Table 3) (19).

The baseline features of patients with and without cardiovascular events are shown in Table 4.

Patients with cardiovascular events were older ($p=0.04$), had an higher PASI ($p=0.001$), longer time elapsing since psoriasis diagnosis ($p=0.04$), and higher prevalence of hypertension ($p=0.002$).

Cardiological therapy and specific therapy for psoriasis were comparable in the two groups.

Hyperemic (during adenosine infusion) diastolic coronary flow and CFR were lower in patients with MACE (57 [48-61] vs 70 [60-80] cm/s, 2.1 ± 0.2 vs 3.1 ± 0.7 ; $p=0.03$ and $p=0.001$, respectively). CMD was present in 18 (12.2%) patients without MACE and in all 5 (100%) patients with MACE ($p<0.0001$). Figure 1 shows the cumulative survival free from cardiovascular events according to the presence of CMD. The prevalence of hypertension was the only difference between patients with CMD and MACE and patients with CMD without MACE (80% vs 27.8%, $p=0.03$). PASI tended to be higher in patients with CMD and MACE compared with patients with CMD without MACE ($p=0.06$). In unadjusted logistic regression analysis, CMD was a significant risk factor for MACE (OR

9.9 (95% CI 6.1-15.8), $p < 0.0001$. Univariable prediction of cardiovascular events is presented in Table 5.

Discussion

In this study, we found CFR to be reduced in 15% of asymptomatic psoriasis patients without evidence of epicardial coronary stenosis. Of note, our study patients were relatively young (mean age 36 years) and with a rather low prevalence of traditional CV risk factors. This is in agreement with previous studies that reported abnormal CFR in patients with psoriasis or other systemic inflammatory diseases (such as SLE, ankylosing spondylitis, RA, inflammatory bowel disease) with normal coronary arteries, indicating that microcirculation may be affected before the occurrence of coronary atherosclerosis (1,8).

Most importantly, CFR was found to predict MACE-free survival in our psoriasis patients. Patients with CMD had significantly worse outcome than patients without CMD. Twenty one percent of psoriasis patients with an impaired CFR developed a MACE. This is an impressive outcome considering the age of our study patients, ranging from 18 to 50 years.

Patients affected by severe psoriasis show increased risk of premature CV events and death (20-22). Traditional CV risk factors appear to contribute to cardiovascular events development in patients with severe psoriasis. However, the increased risk noted in this common inflammatory condition is not completely captured by traditional risk assessment, and persists beyond adjustment for these factors. The analysis of the General Practice Research Database showed that patients with severe psoriasis had a 53% (23) and 57% (20) increased risk for major adverse cardiac events and CV mortality, respectively, after adjusting for age, gender, diabetes, hypertension, tobacco use, and hyperlipidemia.

1 As inflammation is a critical component of atherosclerosis pathophysiology, chronic inflammation
2 in psoriasis patients may play a significant role in the shared mechanisms driving accelerated-
3 atherosclerosis. During a psoriasis flare, there are more than 1 billion immune cells activated
4 within the body. Psoriasis is characterized by increased pro-inflammatory cytokine levels and
5 activation of myeloid dendritic cells, neutrophils, and Th cells (mostly Th17). T cells secrete
6 intermediates (e.g., IL-17F, IL-17A, and IL-22), which, in turn, activate keratinocytes and further
7 stimulate the production of pro-inflammatory cytokines. IL-17A, IL-1, and TNF- α play also a role in
8 atherosclerosis by driving cell-mediated immunity.

9
10 The prognostic value of an impaired CFR has been well demonstrated in several groups of patients,
11 even without coronary artery disease (24-26). In fact, impaired CFR might not only represent the
12 extent of disease in conductance vessels but might also be related to pure microvascular
13 vasomotor dysfunction, because in the absence of hemodynamically significant stenosis maximal
14 increase of blood flow is predominantly determined by resistance vessels of the coronary
15 microcirculation. Intriguingly, a reduced CFR has been showed to predict a worse cardiovascular
16 prognosis also in asymptomatic patients with diabetes (27) or systemic sclerosis (10). In our study
17 patients, CFR impairment was not associated to significant coronary artery disease. These findings
18 are suggestive of CMD, which may represent an early marker of accelerated coronary
19 atherosclerosis and contribute to the increased cardiovascular morbidity and mortality in these
20 patients. In keeping with this, our study suggests that CMD may precede, at least in some cases,
21 the onset of an epicardial disease, susceptible of percutaneous or surgical revascularization.
22
23 Indeed, coronary arteries were normal at MSCT at the time of CFR assessment in all our patients
24 with type 1 myocardial infarction.

25
26 Systemic inflammation has been shown to be an important risk factor for CMD, similarly to
27 traditional CV risk factors, such as smoking, diabetes mellitus, hypertension, and hyperlipidemia

(1, 28-31). In our population, a blunted CFR was associated with a severe psoriasis and the presence of psoriatic arthritis, both associated with a higher systemic inflammatory burden (32, 33). In this context, a psoriasis/psoriatic arthritis-specific element appears to contribute to the CMD and the increased cardiovascular risk associated with psoriasis, although the precise nature of this remains to be determined. Soluble factors including increased levels of the pro-inflammatory cytokines, TNF- α and IL-17, may be important. TNF- α may impair the activation of endothelial nitric oxide synthase (eNOS), degrade eNOS mRNA, alter vasomotor function acting on vascular smooth muscle cells and induces oxidative stress by increasing the production of reactive oxygen species (34). Some studies reported that also in healthy individuals circulating levels of several different pro-inflammatory cytokines, in particular IL-6 and TNF- α , are associated with risk of CV outcomes in an approximately log-linear manner (35, 36). IL-6 is able to promote differentiation of naive Th cells into Th17 cells, that represent the most important pathogenic cell in psoriasis lesions development (37). In the last years, inhibitors of IL-17 and TNF- α have become available in the treatment of psoriasis and other inflammatory diseases. Non-randomized data from biological registries suggest that TNF- α blocking therapy could reduce CV risk in patients affected by rheumatological and dermatological diseases (38).

We have recently reported that CMD improves after treatment with TNF- α inhibitors in patients with established psoriasis (9). Therefore, it is plausible that chronic inflammation represents the linking mechanism between psoriasis, CMD and increased CV risk, and that anti-inflammatory treatment may help to reduce this risk.

The results of the present study have a potential impact in the management of patients with psoriasis. Cardiovascular risk stratification of patients with psoriasis remains a difficult clinical problem. Since psoriasis patients face an increased risk of coronary artery disease, it is important to identify patients at higher risk for developing cardiovascular complications in order to reduce

1 morbidity and mortality. Screening by noninvasive Doppler-derived CFR might represent a
2 valuable, safe and inexpensive tool for assessing the presence and prognostic effect of macro- and
3 microvascular disease in patients with psoriasis. In our opinion no further cardiological deepening
4 might be justified for patients with $CFR > 2.5$, because of their low risk for future cardiac events. On
5 the contrary, strict follow-up should be considered for patients with $CFR \leq 2.5$. In these higher risk
6 patients, an aggressive strategy, including the careful management of conventional CV risk factors,
7 seems to represent the logical approach. Optimizing cardiovascular prevention and care in this
8 patient population should involve close liaison between cardiologists and dermatologists.
9 Furthermore, the control of psoriasis and its related systemic inflammation using powerful drugs
10 blocking major drivers of skin and vascular inflammation (namely $TNF-\alpha$ and IL-17), may eventually
11 impart benefits toward overall CV risk. Recently, CANTOS study showed that IL-1 inhibition by
12 Canakinumab inhibition given once every three months among patients with a prior myocardial
13 infarction and a persistent increase in C-reactive protein reduced the hazard ratio for
14 cardiovascular events of 15% compared with placebo (4).
15 Further studies need to provide more insights on the duration of improvement of CMD obtained
16 with appropriate psoriasis therapy during time and the real impact of a recover of blunted CFR on
17 future cardiovascular outcomes in these patients.
18 As outlined above, the mechanism of atherogenesis as well as the coronary microvascular
19 dysfunction is mainly considered an inflammatory process. Supporting this view, many studies
20 have shown that also a low-grade systemic inflammation leads to an increased risk of
21 cardiovascular events. Diet is one of the most important factors that can affect the inflammatory
22 process and oxidative stress, and it could actually represent a good and relatively easy point of
23 intervention to reduce the risk of cardiovascular disease. Indeed, some foods may have a
24 proinflammatory effect and increase oxidative stress, while others may have a beneficial effect

(39). For example, the Western diet, mainly characterized by meat consumption, is positively associated with inflammatory biomarkers, while the Mediterranean diet has been shown to reduce some inflammatory biomarkers. Several studies have evaluated the role of individual nutrients on psoriasis (40). In particular, the greater adherence to the Mediterranean diet is associated with a lesser severity of psoriasis, both objective and subjective, independently of the modality of treatment and the presence of obesity, and lower levels of C-reactive protein (41). In this context, we are not able to exclude the possible effect of the diet on the microcirculatory function in our patients. However, this influence seems unlikely as our patients' diet did not differ significantly and our patients also came largely from the same geographical area and not from areas with different eating habits.

Some important limitations need to be taken into account in the present study. It is a retrospective study, with a small sample size and with few events. The small sample size and few events did not allow us to perform a survival multivariable analysis and mostly error and non-reproducible may also occur. Even though caution must be applied while extrapolating our results, we believe our sample might be representative of the region since our medical center is a high volume reference for psoriasis and CFR assessment. There may be an inherent selection bias because of its nonrandomized design. A large-scale randomized controlled trial would be ideal. Further larger trials with larger patient populations should be performed to confirm our data and, more importantly, to establish the potential beneficial role of reversing CMD by interventional strategies for long-term atherosclerotic disease progression.

Clinical perspective

Our findings confirm a novel role of coronary microcirculation in the pathophysiology of cardiovascular disease in severe psoriasis. CFR by TDE may be a noninvasive, simple, and objective diagnostic tool for the assessment and follow-up of coronary microvascular function in these

patients. Moreover, our data may improve the management and treatment of psoriasis in its cardiac asymptomatic initial phase and may explain why the disease is associated with increased cardiovascular morbidity and risk, although molecular mechanisms involved need to be further investigated.

Conclusions

The results of the present study provide evidence that CMD is associated with a greater severity of psoriasis and the presence of psoriatic arthritis, both increasing the burden of inflammation, and hypertension. Moreover, our study suggests that psoriasis patients with CMD carry a higher risk of cardiovascular events over a long-term follow up. These results not only provide a rationale for using CFR determination for cardiovascular risk assessment in psoriasis patients, but also reinforce the concept of systemic inflammation as a prognostic parameter for CMD and, eventually, for adverse long-term CV outcome. Whether novel biologic therapies able to reduce skin disease will improve CMD and prognosis in these patients needs to be further studied, prospectively.

References

1. Faccini A, Kaski JC, Camici PG. Coronary microvascular dysfunction in chronic inflammatory rheumatoid diseases. *Eur Heart J* 2016;37(23):1799-1806.
2. Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, et al. Risk of myocardial infarction in patients with psoriasis. *JAMA* 2006;296(14):1735-41.
3. Lerman JB, Joshi AA, Chaturvedi A, Abera TM, Dey AK, et al. Coronary Plaque Characterization in Psoriasis Reveals High-Risk Features That Improve After Treatment in a Prospective Observational Study. *Circulation* 2017;136(3):263-276.
4. Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, et al. CANTOS Trial Group. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. *N Engl J Med* 2017;377(12):1119-1131.
5. Elnabawi YA, Dey AK, Goyal A, Groenendyk JW, Chung JH, et al. Coronary artery plaque characteristics and treatment with biologic therapy in severe psoriasis: results from a prospective observational study. *Cardiovasc Res*. 2019;115:721-728.
6. Wu JJ, Poon K-YT, Channual JC, Shen AY-J. Association between tumor necrosis factor inhibitor therapy and myocardial infarction risk in patients with psoriasis. *Archives of Dermatology* 2012;148:1244-1250.
7. Camici PG, Crea F. Coronary microvascular dysfunction. *N Engl J Med* 2007;356:830–840.
8. Osto E, Piasterico S, Maddalozzo A, Forchetti G, Montisci R, et al. Impaired coronary flow reserve in young patients affected by severe psoriasis. *Atherosclerosis* 2012;221(1):113-117.
9. Piasterico S, Osto E, Famoso G, Zanetti I, Gregori D, et al. Treatment with tumor necrosis factor inhibitors restores coronary microvascular function in young patients with severe psoriasis. *Atherosclerosis* 2016;251:25-30.
10. Vacca A, Montisci R, Garau P, Siotto P, Piga M, et al. Prognostic impact of coronary microcirculation abnormalities in systemic sclerosis: A prospective study to evaluate the role of noninvasive tests. *Arthritis Res Ther* 2013;15:R8.
11. Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. *Am J Cardiol* 1986; 57:450-458.
12. Nagueh SF, Appleton CP, Gillebert TC, Marino PN, Oh JK, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. *J Am Soc Echocardiogr* 2009; 22:107-133.
13. Redfield MM, Jacobsen SJ, Burnett JC Jr., Mahoney DW, Balley KR, et al. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. *JAMA* 2003; 289:194-202.
14. Tona F, Caforio ALP, Montisci R, Gambino A, Angelini A, et al. Coronary flow velocity pattern and coronary flow reserve by contrast-enhanced transthoracic echocardiography predict long-term outcome in heart transplantation. *Circulation*. 2006;114(Suppl. I):I-49–55.
15. Rubinshtein R, Yang EH, Rihal CS, Prasad A, Lennon RJ, et al. Coronary microcirculatory vasodilator function in relation to risk factors among patients without obstructive coronary disease and low to intermediate Framingham score. *Eur Heart J*. 2009;31:936–942.
16. Russo V, Zavalloni A, Bacci Reggiani ML, Buttazzi K, Gostoli V, et al. Incremental prognostic value of coronary CT angiography in patients with suspected coronary artery disease. *Circ Cardiovasc Imaging* 2010; 3:351-359.

17. Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, et al. Executive Group on behalf of the Joint European Society of Cardiology (ESC)/American College of Cardiology (ACC)/American Heart Association (AHA)/World Heart Federation (WHF) Task Force for the Universal Definition of Myocardial Infarction. *J Am Coll Cardiol* 2018;18:2231-2264.
18. Roffi M, Patrono C, Collet JP, Mueller C, Valgimigli M, et al. ESC Scientific Document Group. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). *Eur Heart J* 2016; 37, 267–315.
19. Tamis-Holland JE, Jneid H. Myocardial Infarction with nonobstructive coronary arteries (MINOCA): It's time to face reality! *J Am Heart Assoc.* 2018;7(13). pii: e009635.
20. Mehta NN, Azfar RS, Shin DB, Neimann AL, Troxel AB, et al. Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database. *Eur Heart J* 2010; 31: 1000–1006.
21. Gelfand JM, Troxel AB, Lewis JD, Kurd SK, Shin DB, et al. The risk of mortality in patients with psoriasis: results from a population-based study. *Arch Dermatol* 2007; 143: 1493–1499.
22. Brauchli YB, Jick SS, Miret M, Meier CR. Psoriasis and risk of incident myocardial infarction, stroke or transient ischaemic attack: an inception cohort study with a nested case-control analysis. *Br J Dermatol* 2009;160:1048–1056.
23. Mehta NN, Yu Y, Pinnelas R, Krishnamoorthy P, Shin DB, et al. Attributable risk estimate of severe psoriasis on major cardiovascular events. *Am J Med* 2011;124:775e1-775e6.
24. Sicari R, Rigo F, Cortigiani L, Gherardi S, Galderisi M, et al. Additive prognostic value of coronary flow reserve in patients with chest pain syndrome and normal or near-normal coronary arteries. *Am J Cardiol* 2009;103:626–631.
25. Nakanishi K, Fukuda S, Shimada K, Miyazaki C, Otsuka K, et al. Impaired coronary flow reserve as a marker of microvascular dysfunction to predict long-term cardiovascular outcomes, acute coronary syndrome and the development of heart failure. *Circ J* 2012;76: 1958-1964.
26. Cortigiani L, Rigo F, Gherardi S, Galderisi M, Bovenzi F, et al. Prognostic meaning of coronary microvascular disease in type 2 diabetes mellitus: a transthoracic Doppler echocardiographic study. *J Am Soc Echocardiogr* 2014;27(7):742-748.
27. Kawata T, Daimon M, Hasegawa R, Toyoda T, Sekine T, et al. Prognostic value of coronary flow reserve assessed by transthoracic Doppler echocardiography on long-term outcome in asymptomatic patients with type 2 diabetes without overt coronary artery disease. *Cardiovascular Diabetology* 2013, 12:121-128.
28. Arroyo-Espiguero R, Mollichelli N, Avanzas P, Zouridakis E, Newey VR, et al. Chronic inflammation and increased arterial stiffness in patients with cardiac syndrome X. *Eur Heart J* 2003;24:2006–2011.
29. Caliskan M, Erdogan D, Gullu H, Yilmaz S, Gursoy Y, et al. Impaired coronary microvascular and left ventricular diastolic functions in patients with ankylosing spondylitis. *Atherosclerosis* 2008; 196: 306–312.
30. Recio-Mayoral A, Mason JC, Kaski JC, Rubens MB, Harari OA, et al. Chronic inflammation and coronary microvascular dysfunction in patients without risk factors for coronary artery disease. *Eur Heart J* 2009; 30: 1837–1843.
31. Kaufmann PA, Gneccchi-Ruscione T, Di TM, Schafers KP, Luscher TF, et al. Coronary heart disease in smokers: vitamin C restores coronary microcirculatory function. *Circulation* 2000;102:1233–1238.

32. Asahina A, Umezawa Y, Yanaba K, Nakagawa H. Serum C-reactive protein levels in Japanese patients with psoriasis and psoriatic arthritis: Long-term differential effects of biologics. *J Dermatol*. 2016 Jul;43(7):779-784.
33. Snekvik I, Nilsen TIL, Romundstad PR, Saunes M. Psoriasis and cardiovascular disease risk factors: the HUNT Study, Norway. *J Eur Acad Dermatol Venereol*. 2018 May;32(5):776-782.
34. Zhang H, Park Y, Wu J, Chen Xp, Lee S, et al. Role of TNF-alpha in vascular dysfunction. *Clin Sci* 2009;116(3):219-230.
35. Woodward M, Welsh P, Rumley A, Tunstall-Pedoe H, Lowe GD. Do inflammatory biomarkers add to the discrimination of cardiovascular disease after allowing for social deprivation? Results from a 10-year cohort study in Glasgow, Scotland. *Eur Heart J*. 2010 Nov;31(21):2669-2675.
36. Kaptoge S, Seshasai SR, Gao P, Freitag DF, Butterworth AS, et al. Inflammatory cytokines and risk of coronary heart disease: new prospective study and updated meta-analysis. *Eur Heart J*. 2014 Mar;35(9):578-589.
37. Beringer A, Noack M, Miossec P. IL-17 in Chronic Inflammation: from discovery to targeting. *Trends Mol Med* 2016;22(3):230-241.
38. Puig L. Cardiometabolic comorbidities in psoriasis and psoriatic arthritis. *Int J Mol Sci* 2017 25;19:58-74.
39. Minihane AM, Vinoy S, Russell WR, Baka A, Roche HM, et al. Low-grade inflammation, diet composition and health: current research evidence and its translation. *Br J Nutr*. 2015;114:999-1012.
40. Molina-Leyva A, Cuenca-Barrales C, Vega-Castillo JJ, Ruiz-Carrascosa JC, Ruiz-Villaverde R. Adherence to mediterranean diet in spanish patients with psoriasis: cardiovascular benefits? *Dermatol Ther*. 2019;32:e12810.
41. Phan C, Touvier M, Kesse-Guyot E, Adjibade M, Hercberg S, et al. Association between mediterranean anti-inflammatory dietary profile and severity of psoriasis: results from the NutriNet-Santé Cohort. *JAMA Dermatol*. 2018;154:1017-1024.

Funding

Dr. Osto is recipient of the Swiss National Science Foundation PRIMA Grant (PR00P3_179861/1) and of the Swiss Card-Onco-Grant (Alfred and Annemarie von Sikk Grant) at the Institute of Clinical Chemistry, University Hospital Zurich, Zurich, Switzerland.

Author contributions

Stefano Piaserico: conceived of the presented idea, wrote the manuscript

Elena Osto: conceived of the presented idea, wrote the manuscript

Giula Famoso: Performed the CFR and contributed to the analysis of the results

Roberta Montisci: performed the statistical analysis

Laura De Michieli: Performed the CFR and contributed to the analysis of the results

Irene Zanetti: collected the data

Sabino Iliceto: supervised the project

Francesco Tona: conceived of the presented idea, designed and directed the project

Figures legends

Figure 1: Kaplan Meier cardiac event-free survival curves: comparison of patients with or without CMD ($p<0.0001$).

Reviewer #1: The Authors are mentioning MINOCA in the revised version (page 8); however, a proper reference to this type of MI (not known by general Readers) is missing (10.1161/JAHA.118.009635).

Thank you for your suggestion. We added a reference related to MINOCA (new ref. 19)

Statement of Originality – Atherosclerosis

Manuscript Title: Long-term prognostic value of coronary flow reserve in psoriasis patients

List of all Authors: Stefano Piaserico, MD, PhD; Elena Osto, MD, PhD; Giulia Famoso, MD, PhD; Roberta Montisci, MD; Laura De Michieli, MD; Irene Zanetti, MD; Sabino Iliceto, MD; Francesco Tona, MD, PhD

Corresponding Author: Francesco Tona

This statement is to certify that all authors have seen and approved the manuscript being submitted, have contributed significantly to the work, attest to the validity and legitimacy of the data and its interpretation, and agree to its submission to the Atherosclerosis. We attest that the article is the Authors' original work, has not received prior publication and is not under consideration for publication elsewhere.

On behalf of all Co-Authors, the corresponding Author shall bear full responsibility for the submission.

DIPARTIMENTO DI SCIENZE CARDIOLOGICHE,
TORACICHE E VASCOLARI
CLINICA CARDIOLOGICA
Direttore: Prof. Sabino ILICETO



UNIVERSITÀ
DEGLI STUDI
DI PADOVA

via Giustiniani, 2
35100 Padova
tel +39 049 8211844 - 8642
fax +39 049 8211802
francesco.tona@unipd.it
CF 80006480281
P.IVA 00742430283

Francesco Tona, MD, PhD
Dpt. of Cardiac, Thoracic and
Vascular Sciences
University of Padova
Via Giustiniani 2
35128, Padova
Italy

July 14th, 2019

Dear Professor Arnold von Eckardstein,
Universitätsspital Zürich, Zürich, Switzerland

Please find you in the attached file the revised version of our manuscript entitled: “**Long-term prognostic value of coronary flow reserve in psoriasis patients**”, which we would like to resubmit to *Atherosclerosis*.

We thank the Editor and reviewers for the potential interest in our work

We answered to all query of the reviewers.

We hope that our manuscript will be of interest and suitable to be published in such a prestigious scientific journal. This is an original research, it has not been previously published and has not been submitted for publication elsewhere while under your consideration.

All authors have read and approved the manuscript submission.

I guarantee that the authors do not have direct and indirect conflicts of interest which relate directly or indirectly to the subject of the work and nothing to disclose. I will be the corresponding author.

Looking forward to have a chance to hear from you soon, we remain

Sincerely yours

Prof. Francesco Tona, MD, PhD

Francesco Tona, MD, PhD
Division of Cardiology
Dept of Cardiac, Thoracic and Vascular Sciences
University of Padova-Policlinico
Via Giustiniani, 2
35128 Padova, Italy
Tel +3949 8211844; Fax: +3949 821 1802

**DIPARTIMENTO DI SCIENZE CARDIOLOGICHE,
TORACICHE E VASCOLARI**
CLINICA CARDIOLOGICA
Direttore: Prof. Sabino ILICETO

♦ **UNIVERSITÀ DEGLI STUDI DI PADOVA**

E-mail: francescotona@hotmail.com; francesco.tona@unipd.it

Conflicts of Interest – Atherosclerosis

Manuscript Title: Long-term prognostic value of coronary flow reserve in psoriasis patients


List of all Authors: Stefano Piaserico, MD, PhD; Elena Osto, MD, PhD; Giulia Famoso, MD, PhD; Roberta Montisci, MD; Laura De Michieli, MD; Irene Zanetti, MD; Sabino Iliceto, MD; Francesco Tona, MD, PhD

Corresponding Author: Francesco Tona

This statement is to certify that all authors have seen and approved the manuscript being submitted, have contributed significantly to the work, attest to the validity and legitimacy of the data and its interpretation, and agree to its submission to the Atherosclerosis. Also, all authors have no financial conflicts of interest.

On behalf of all Co-Authors, the corresponding Author shall bear full responsibility for the submission.

Figure 1
[Click here to download high resolution image](#)



Supplementary Material for online publication only

[Click here to download Supplementary Material for online publication only: Supplemental_material.docx](#)

Table 1

Table 1. Clinical characteristics of the study population, stratified by presence or absence of coronary microvascular dysfunction (CMD; CFR≤2.5)

	All patients (n=153)	CMD present (CFR 2.0±0.4, range 1.2-2.5; n=23)	CMD absent (CFR 3.3±0.6, range 2.6-6.3; n=130)	p
Age, years	36±8	40±9	36±7	0.03
Males, n (%)	122 (79.7)	20 (87)	102 (78.5)	0.5
PASI	15 [11-20]	18 [11-20]	13 [11-15]	0.02
time elapsing since psoriasis diagnosis, years	16 [10-22]	17 [10-26]	14 [9-21]	0.03
Presence of PsA, n (%)	50 (32.6)	11 (47.8)	39 (30)	0.03
BMI, Kg/m ²	26.39±4	25.76±3.91	26.48±4.01	0.4
Hypertension, n (%)	24 (15.8)	9 (39.1)	15 (11.6)	0.003
Family history of heart disease, n (%)	36 (23.5)	10 (43.4)	26 (20)	0.02
Current smoking, n (%)	52 (33.9)	8 (34.8)	44 (33.8)	0.6
Previous smoking, n (%)	43 (28.1)	5 (21.7)	38 (29.2)	0.7
SBP, mmHg	121±14	124±15	121±14	0.5
DBP, mmHg	76±11	75±7	76±12	0.6
Total cholesterol, mg/dL	194.74±43.17	203.56±42.43	193.31±43.31	0.3
Triglycerides, mg/dL	110.53±61.96	113.50±80.61	110.05±58.80	0.8
hsCRP, mg/L	2.39±3.26	3.24±1.81	2.31±3.37	0.4

BMI, Body Mass Index; CFR, coronary flow reserve; CMD, coronary microvascular dysfunction; hsCRP, high sensitive-C reactive protein; PASI, Psoriasis Area Severity Index; PsA, psoriatic arthritis. DBP, diastolic blood pressure; SBP, systolic blood pressure. Data are presented as mean ± SD

Table 2

Table 2: Factors independently associated with coronary microvascular dysfunction (CFR≤2.5)

	OR	95% CI	p
Model 1: obtained by stepwise logistic regression (<i>C-statistic</i> = 0.80; <i>R</i>² = 0.62)			
Age	1	0.9-1.1	0.6
Time elapsing since psoriasis diagnosis>6 years	2.02	1.4-5.4	0.03
Hypertension	4.4	1.4-13.4	0.007
Model 2: obtained also including variables marginally significant (<i>p</i>≤0.1) (<i>C-statistic</i> = 0.78; <i>R</i>² = 0.61)			
Age	1	0.8-1.09	0.8
Time elapsing since psoriasis diagnosis >6 years	1.9	1.2-4.6	0.03
Hypertension	4.1	1.3-12.1	0.009
PASI>10	3.1	1.1-8.7	0.03
PsA	2.9	1.07-8.1	0.03
Model 3: obtained forcing other variables (<i>C-statistic</i> = 0.87; <i>R</i>² = 0.70)			
Age	1	0.8-1.06	0.7
Time elapsing since psoriasis diagnosis >6 years	1.7	1.2-3.8	0.03
Hypertension	3.6	1.2-9.1	0.02
PASI>10	1.8	1.3-6.2	0.04
PsA	1.8	1.04-6.1	0.07

CI indicates confidence interval; OR, odds ratio. The following variables were considered by the stepwise procedure but were not included in the final models because they did not meet the criteria to enter or to stay in the model: male gender, hsCRP. The following variables were forced into the model one at a time, but their inclusion did not significantly affect the relationship between coronary flow reserve ≤2.5 and variables of model 1: current smoking, BMI, and total cholesterol.

Table 3

Table 3: Demographic and clinical characteristics of patients with events

No.	Age/gender	Time from diagnosis (years)	Type of MI	Psoriasis treatment	Angiographic CAD	Revascularization Therapy	Time from CFR (months)	CFR
1	44/M	26	MINOCA*	Infliximab	none	/	5	2.3
2	38/M	7	Type 1 MI^	Acitretin	70% LAD	PTCA+DES	4	1.8
3	45/M	6	MINOCA*	Ustekinumab	none	/	77	2.0
4	53/M	39	Type 1 MI^	Etanercept	90% RCA	PTCA+DES	2	2.2
5	46/M	23	Type 1 MI^	Adalimumab	TCO Cx, 80% LAD, 70% PDA	CABG	100	2.3

CABG, coronary artery bypass graft surgery; DES, drug eluting stent; LAD, left anterior descending coronary artery; MI, myocardial infarction; MINOCA, myocardial infarction with non-obstructive coronary arteries; PDA, posterior descending coronary artery; PTCA, percutaneous transluminal coronary angioplasty; RCA, right coronary artery; TCO total coronary occlusion. Other abbreviations as in Table 1.

*MINOCA: MI with no angiographic obstructive coronary artery disease (≥50% diameter stenosis in a major epicardial vessel).

^ Type 1 myocardial infarction: MI caused by atherothrombotic coronary artery disease and usually precipitated by atherosclerotic plaque disruption (rupture or erosion).

Table 4

Table 4. Clinical characteristics of patients with and without cardiovascular events

	MACE (n=5)	No MACE (n=148)	p
Age, years	43±6	36±8	0.04
Males, n (%)	5 (100)	117 (79)	0.3
PASI	15 (7-31)	10 (3-15)	0.001
Time elapsing since psoriasis diagnosis, years	13 (4-25)	6 (3-11)	0.04
Presence of PsA, n (%)	2 (40)	48 (32)	0.4
BMI, m ² /Kg	27±5	26±4	0.7
Hypertension, n (%)	4 (80)	21 (14)	0.002
Family history of heart disease, n (%)	0 (0)	36(24)	0.2
Current smoking, n (%)	0 (0)	54 (36)	0.1
Previous smoking, n (%)	0 (0)	50 (33)	0.1
SBP, mmHg	122±22	121±14	0.9
DBP, mmHg	77±12	76±11	0.8
Total cholesterol, mg/dL	200±18	194±43	0.8
Triglycerides, mg/dL	94±65	110±62	0.7
hsCRP, mg/L	2.1±0.2	2.4±0.7	0.1
hDFV, cm/s	57 (48-61)	70 (60-80)	0.03
CFR	2.1±0.2	3.1±0.7	0.001

hDFV, hyperemic diastolic flow velocity. Other abbreviations as in Table 1. Data are presented as mean ± SD or as median with first and third quartiles (Q1-Q3).

Table 5

Table 5. Univariable prediction of cardiovascular events by logistic regression analysis

	OR	95% CI	p
Age, years	1.14	0.99-1.3	0.04
Males, n (%)	0.8	0.69-1.01	0.9
PASI	1.2	1.1-1.32	0.02
Time elapsing since psoriasis diagnosis, years	1.68	1.02-2.76	0.04
Presence of PsA, n (%)	3.13	1.91-19.6	0.2
BMI, m ² /Kg	1.02	0.83-1.26	0.8
Hypertension, n (%)	24	2.6-34	0.005
Family history of heart disease, n (%)	1.26	0.13-11.7	0.8
Current smoking, n (%)	0.81	0.62-1.31	0.9
Previous smoking, n (%)	0.96	0.78-1.23	0.9
SBP, mmHg	1.0	0.93-1.07	0.9
DBP, mmHg	1.0	0.92-1.09	0.8
Total cholesterol, mg/dL	1.01	0.99-1.04	0.2
Triglycerides, mg/dL	1.0	0.98-1.02	0.8
hsCRP, mg/L	1.8	1.3-2.14	0.2
hDFV, cm/s	1.03	1.0-1.1	0.1
CFR	7.81	1.93-31.2	0.004

Abbreviations as in Table 1 and 4.

Atherosclerosis style guide checklist

Atherosclerosis applies format guidelines to all accepted papers, with the aim of improving their readability.

Manuscripts that do not conform to the format guidelines of the *Atherosclerosis* Journal will be returned to the authors for reformatting.

Please find below a questionnaire to guide authors to comply with the formatting requirements for revised submissions. For more detailed information, visit [our website](#).

Please note that when you answer “No” to a question, editing of your manuscript is required before submission to *Atherosclerosis*.

Manuscript structure and style

Does your manuscript contain all the below essential elements, in this order? **Yes**
(please stick to the headers as indicated below)

- Title
- Authors, Affiliations, Contact Information
- Abstract in the Atherosclerosis format (*Background and aims, Methods, Results, Conclusions*)
- Introduction
- Materials and methods (or Patients and methods)
- Results
- Discussion
- Conflict of interest (mandatory)
- Financial support (if applicable)
- Author contributions (mandatory)
- Acknowledgements (if applicable)
- References
- Figures and Tables (with legends in the suitable style)

Abstract style

Is the Abstract structured in the below sections? **Yes**

- *Background and aims*
- *Methods*
- *Results*
- *Conclusions*

Figure and table legends

Are figure and table legends formatted as described below? **Yes**

Each figure and table legend should have a brief overarching title that describes the entire figure without citing specific panels, followed by a description of each panel, and all symbols used.

If a figure or table contains multiple panels, the letter describing each panel should be capitalized and surrounded by parenthesis: i.e. (A)(B)(C)(D).

Please make sure to apply the formatting requirements to figures and tables where necessary (e.g. style of *p* values, gene and protein nomenclature).

Footnotes to tables

Are footnotes to tables formatted as described below? **Yes**

Footnotes to tables should be listed with superscript lowercase letters, beginning with “^a.”
Footnotes must not be listed with numbers or symbols.

Abbreviations

Are abbreviations defined when first used in the text? **Yes**

Use of abbreviations should be kept at a minimum.

Units

Are units expressed following the international system of units (SI)?

Yes

If other units are mentioned, please provide conversion factors into SI units.

DNA and protein sequences

Are gene names italicized?

Yes

Gene names should be italicized; protein products of the loci are not italicized.

For murine models, the gene and protein names are lowercase except for the first letter.
(e.g., gene: *Abcb4*; protein: Abcb4)

For humans, the whole gene name is capitalized.
(e.g., gene: *ABCB4*; protein ABCB4)

Mouse strains and cell lines

Are knock-out or transgenic mouse strains and cell lines italicized and the symbol superscripted? Yes

(e.g. *ob/ob* , *p53^{+/+}* , *p53^{-/-}*)

p values

Are *p* values consistently formatted according to the below style throughout the manuscript (including figures and tables)?

Yes

$p < X$

$p > X$

$p = X$

Language

Is your manuscript written in good English?

Yes

Please make sure that you consistently use either American or British English, but not a mixture of them.

Please make sure that words are written consistently in the same way throughout the manuscript.

e.g. non-significant or nonsignificant

e.g. down-regulation or downregulation

Artwork

Have you submitted high-resolution versions of your original artwork?

Yes

Please make sure to use uniform lettering and sizing in your original artwork, including letters to indicate panels, consistently throughout all figures.